Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 38232341

Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2024 Mar 20
First author
De La Fouchardière C

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Ann Transl Med. 2025 Feb 28;13(1):9. doi: 10.21037/atm-24-182.
    note
    Source null
    related pmid
    40115057
    relationship
    Comment in

Authors and identifiers

  1. name
    De La Fouchardière C
    type
    Author
  2. name
    Malka D
    type
    Author
  3. name
    Cropet C
    type
    Author
  4. name
    Chabaud S
    type
    Author
  5. name
    Raimbourg J
    type
    Author
  6. name
    Botsen D
    type
    Author
  7. name
    Launay S
    type
    Author
  8. name
    Evesque L
    type
    Author
  9. name
    Vienot A
    type
    Author
  10. name
    Perrier H
    type
    Author
  11. name
    Jary M
    type
    Author
  12. name
    Rinaldi Y
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    De La Fouchardière C
    type
    Author
  2. name
    Malka D
    type
    Author
  3. name
    Cropet C
    type
    Author
  4. name
    Chabaud S
    type
    Author
  5. name
    Raimbourg J
    type
    Author
  6. name
    Botsen D
    type
    Author
  7. name
    Launay S
    type
    Author
  8. name
    Evesque L
    type
    Author
  9. name
    Vienot A
    type
    Author
  10. name
    Perrier H
    type
    Author
  11. name
    Jary M
    type
    Author
  12. name
    Rinaldi Y
    type
    Author
bibliography ids
  1. nci-bib-29d9443b5304301a530946c8
book metadata
content sha256
24b1f41162d8b235855552605e1daab3e89dd14e0bec0ea6e37f1e42edc0e1fd
document type
citation
dois
  1. 10.1200/JCO.23.00795
electronic publication date
display
2024 Jan 17
precision
day
year
2024
evidence scope
bibliographic_metadata_only
id
pubmed:38232341
immutable id
pubmed:38232341@24b1f41162d8b235855552605e1daab3e89dd14e0bec0ea6e37f1e42edc0e1fd
journal
abbreviation
J Clin Oncol
issn electronic
1527-7755
issn print
0732-183X
issue
9
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
1055-1066
volume
42
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Ann Transl Med. 2025 Feb 28;13(1):9. doi: 10.21037/atm-24-182.
    note
    Source null
    related pmid
    40115057
    relationship
    Comment in
outcomes validated
false
pmid
38232341
provenance
batch id
6d213eecf21b6b7867cb
provider
NCBI PubMed ESummary
record sha256
e120aa35cc9264018b8972c0e27d3cf8866725bb7a7c915a21204aa3a228af96
response sha256
684f894a21d8f5f78a3bd0acd8ee4215ff94144487c53dab1056650ee8d6751d
retrieved at
2026-09-09T23:48:19.049083+00:00
publication date
display
2024 Mar 20
precision
day
year
2024
publication types
  1. Randomized Controlled Trial
  2. Clinical Trial, Phase III
  3. Journal Article
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/38232341/
title
Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study.

Preserved source evidence · Not medical advice